drugset / Trial / NCT02455245

A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma

NCT02455245 ↗

Phase 3 Active not recruiting 95 enrolled Alicia Lenzen
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is trying to learn and understand if the chemotherapy drug called carboplatin works as well as the standard therapy. The standard therapy for Low Grade Glioma (LGG) in children and young adults is using a combination of carboplatin and vincristine. Studies in children have shown that the use of carboplatin alone has promise of being just as effective for treating LGG as standard therapy. Additionally, this study will try to understand if treatment with carboplatin alone is associated with an improved quality of life for LGG patients and their families.

Timeline

Start
2015-03
Primary completion
2025-08-31
Completion
2025-11-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 19 mg/kg Intravenous
Subject Carboplatin Small molecule 175 mg/m2 Intravenous
Subject Carboplatin Small molecule 560 mg/m2 Intravenous
Subject Vincristine Small molecule 0.05 mg/kg Intravenous
Subject Vincristine Small molecule 1.5 mg/m2 Intravenous

Indications